<--- Back to Details
First PageDocument Content
Genetics / Single nucleotide polymorphisms / Coagulation system / Rodenticides / Warfarin / Methylenetetrahydrofolate reductase / Factor V Leiden / Thrombin / Thrombophilia / Biology / Chemistry / Blood
Date: 2013-07-18 15:10:51
Genetics
Single nucleotide polymorphisms
Coagulation system
Rodenticides
Warfarin
Methylenetetrahydrofolate reductase
Factor V Leiden
Thrombin
Thrombophilia
Biology
Chemistry
Blood

HOW TO INTERPRET THROMBOPHILIA RISK TEST RESULTS Factor II Gene (Prothrombin) Mutation: 20210G>A

Add to Reading List

Source URL: www.atherotech.com

Download Document from Source Website

File Size: 73,62 KB

Share Document on Facebook

Similar Documents

Center Information: Subcenter: Inland Northwest Blood Center Inland Northwest Blood Center 210 W. Cataldo Ave.

Center Information: Subcenter: Inland Northwest Blood Center Inland Northwest Blood Center 210 W. Cataldo Ave.

DocID: 1riKA - View Document

Microsoft Wordfile00

Microsoft Wordfile00

DocID: 1r9dZ - View Document

News Releases  Global Home | CSL Behring US | CSL Plasma | All CSL Behring Web Sites  

News Releases Global Home | CSL Behring US | CSL Plasma | All CSL Behring Web Sites  

DocID: 1qHpD - View Document

RECOTHROM, Thrombin topical (Recombinant) Package Insert

RECOTHROM, Thrombin topical (Recombinant) Package Insert

DocID: 1qv5K - View Document

Quester leads £3.1million investment in Haemostatix 23 January 2006 – Quester, a leading UK venture capital company, announced today that it has led a £3.1million investment in Haemostatix Ltd, a drug design and deve

Quester leads £3.1million investment in Haemostatix 23 January 2006 – Quester, a leading UK venture capital company, announced today that it has led a £3.1million investment in Haemostatix Ltd, a drug design and deve

DocID: 1qk7W - View Document